A new report launched in the European Parliament shows inefficiencies in the treatment of chronic pain result in increasing health care costs and prolonged patient suffering.
Chronic pain costs Europe billions of euros every year, with national costs ranging from 1.1 billion euros ($1.48 billion) to nearly 50 billion euros. 21% of Europeans with chronic pain are unable to work at all as a result of their chronic pain, and of those able to work, 61% said it had impacted directly on their employment status.
This new research was commissioned for inclusion in a pan-European consensus report, the Pain Proposal, developed by a range of European experts in the fields of chronic pain, policy and economics in partnership with Pfizer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze